Frankman Zachary D, Jiang Linan, Schroeder Joyce A, Zohar Yitshak
Department of Biomedical Engineering, University of Arizona, Tucson, AZ 85721, USA.
Department of Aerospace and Mechanical Engineering, University of Arizona, Tucson, AZ 85721, USA.
Micromachines (Basel). 2022 Jan 20;13(2):152. doi: 10.3390/mi13020152.
Cancer is a disease in which cells in the body grow out of control; breast cancer is the most common cancer in women in the United States. Due to early screening and advancements in therapeutic interventions, deaths from breast cancer have declined over time, although breast cancer remains the second leading cause of cancer death among women. Most deaths are due to metastasis, as cancer cells from the primary tumor in the breast form secondary tumors in remote sites in distant organs. Over many years, the basic biological mechanisms of breast cancer initiation and progression, as well as the subsequent metastatic cascade, have been studied using cell cultures and animal models. These models, although extremely useful for delineating cellular mechanisms, are poor predictors of physiological responses, primarily due to lack of proper microenvironments. In the last decade, microfluidics has emerged as a technology that could lead to a paradigm shift in breast cancer research. With the introduction of the organ-on-a-chip concept, microfluidic-based systems have been developed to reconstitute the dominant functions of several organs. These systems enable the construction of 3D cellular co-cultures mimicking in vivo tissue-level microenvironments, including that of breast cancer. Several reviews have been presented focusing on breast cancer formation, growth and metastasis, including invasion, intravasation, and extravasation. In this review, realizing that breast cancer can recur decades following post-treatment disease-free survival, we expand the discussion to account for microfluidic applications in the important areas of breast cancer detection, dormancy, and therapeutic development. It appears that, in the future, the role of microfluidics will only increase in the effort to eradicate breast cancer.
癌症是一种体内细胞生长失控的疾病;乳腺癌是美国女性中最常见的癌症。由于早期筛查和治疗干预的进步,乳腺癌导致的死亡人数随时间有所下降,尽管乳腺癌仍是女性癌症死亡的第二大主要原因。大多数死亡是由转移引起的,因为乳腺原发性肿瘤中的癌细胞会在远处器官的偏远部位形成继发性肿瘤。多年来,人们一直使用细胞培养和动物模型来研究乳腺癌发生和发展的基本生物学机制,以及随后的转移级联反应。这些模型虽然对于阐明细胞机制极为有用,但主要由于缺乏合适的微环境,对生理反应的预测能力较差。在过去十年中,微流控技术已成为一种可能导致乳腺癌研究范式转变的技术。随着芯片器官概念的引入,基于微流控的系统已被开发出来,以重建多个器官的主要功能。这些系统能够构建模拟体内组织水平微环境(包括乳腺癌微环境)的三维细胞共培养体系。已经有几篇综述聚焦于乳腺癌的形成、生长和转移,包括侵袭、血管内渗和血管外渗。在本综述中,鉴于乳腺癌在治疗后无病生存数十年后仍可能复发,我们将讨论范围扩大到微流控技术在乳腺癌检测、休眠和治疗开发等重要领域的应用。未来,微流控技术在根除乳腺癌的努力中所起的作用似乎只会增加。